Pharmaceutical APIs Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
02:01
May 03
May 03
Rare earths, batteries, pharma APIs strategic
Chamath says the tariff fight has finally put the four things that actually matter on the national agenda: batteries, AI, pharmaceutical APIs and rare earths. His framing is national security rather than trade economics. If China invades Taiwan, or China and India fight and the US has to pick a side, Beijing can simply withhold pharma APIs, rare earths and batteries and set American life back 50 years, so the US currently has no strategic optionality to act on what is morally right. He adds that China's national-champion model, which blurs public and private partnership, law and capital, is the thing the US still has no answer to, and none of this was on the table until April 9.
HIGH
23:55
Apr 11
Apr 11
Onshore active pharmaceutical ingredient production.
Fourth critical area: active pharmaceutical ingredients. Chamath says that when Americans get sick the country must be able to design and manufacture APIs itself, because many of them require convoluted processes and cold chains, and today that capability sits with foreign suppliers whose posture toward the US can change at any moment.
MED
About Pharmaceutical APIs Investor Commentary
Across the available history and selected sources, Buzzberg tracks Pharmaceutical APIs across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Chamath Palihapitiya.